(Phenylsulfonyl)Benzene

(Phenylsulfonyl)Benzene

SCHEMBL1067504

C.O=S(=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.93
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
TSHR P16473 2/20 0.55
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA7 P43166 2/20 0.55
CA13 Q8N1Q1 2/20 0.55
HSD17B10 Q99714 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
CA3 P07451 1/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55
CA5A P35218 1/20 0.55
PLA2G7 Q13093 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
CA5B Q9Y2D0 1/20 0.55
DUSP3 P51452 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(Phenylsulfonyl)Benzene SCHEMBL28119187 0.97 HTR6 (1.00) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL29450723 0.97 HTR6 (1.00) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL29473549 0.97 HTR6 (1.00) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL29775288 0.97 HTR6 (1.00) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL30255 0.97 HTR6 (1.00) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL13735236 0.97 HTR6 (1.00) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL25435825 0.93 HTR6 (0.93) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL9797473 0.93 HTR6 (0.93) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL11362327 0.93 HTR6 (0.93) HTR6ALDH1A1SMN1; SMN2TSHRCA12
(Phenylsulfonyl)Benzene SCHEMBL5537560 0.93 HTR6 (0.93) HTR6ALDH1A1SMN1; SMN2TSHRCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349843-B2 Carboxylic acid derivatives, their preparation and use ABBOTT GMBH & CO. KG (DE) 2013-01-08 US disclosed
US-7863445-B2 Carboxylic acid derivatives, their preparation and use ABBOTT GMBH & CO. KG (DE) 2011-01-04 US disclosed
US-20100076188-A1 NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-03-25 US disclosed
US-6600043-B2 Pyramidine or triazine derivatives which specifically inhibit the binding of endothelin to the receptor BASF AKTIENGESELLSCHAFT (DE) 2003-07-29 US disclosed
US-6197958-B1 CYCLOPENTAPYRIMIDINE DERIVATIVES; ENDOTHELIN RECEPTOR INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-03-06 US disclosed
US-5969134-A CARDIOVASCULAR DISORDERS, VASOCONSTRICTION, HYPOTENSIVE AGENTS AND RELEASE OF ENDOTHELINS BASF AKTIENGESELLSCHAFT (DE) 1999-10-19 US disclosed
EP-0380422-A1 Process to prepare proteins inhibiting lymphocytotoxicity and the complement, and proteins obtained thereby FONDATION NATIONALE DE TRANSFUSION SANGUINE (FR) 1990-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076188-A1 NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE HCAR1, HCAR2, HCAR3 HTR6 1850/4885ALDH1A1 348/4885SMN1; SMN2 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.